Overview

Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer

Status:
Not yet recruiting

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

To compare the objective response rate (ORR) and safety of tislelizumab combined with chemotherapy and Tislelizumab combined with radiotherapy in elderly patients with esophageal cancer with advanced or recurrent metastasis

Phase:

Phase 2

Details

Lead Sponsor:

Fujian Cancer Hospital

Treatments:

Carboplatin
Cisplatin
Paclitaxel